Loreal 2012 Annual Report Download - page 71

Download and view the complete annual report

Please find page 71 of the 2012 Loreal annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 96

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96

Five of the 20 top-selling
products in the dermatology
market(1)
In 2012, GALDERMA sales increased by +5.9%(4),
with particularly good results in Germany,
China (see box) and Australia. In the pre-
scription segment, the laboratory recorded
a good growth rate, thanks to Epiduo™
gel, the number one acne treatment pre-
scribed worldwide(3). Five GALDERMA products
are ranked in the top 20 in the dermatology
prescription segment(1). However, the overall
development of this segment has been
affected by the rise of generic drugs, par-
ticularly in the United States and France.
Given this context, GALDERMA is focusing on
developing its portfolio of self-medication
treatments. In Germany, sales of Loceryl®
have risen sharply since this treatment for
fungal nail infections was made available
over-the-counter in pharmacies and starred
in a vast multimedia advertising campaign
aimed at the general public.
Strong growth for
self-medication products
and aesthetic and corrective
dermatology solutions
Overall, GALDERMA recorded strong growth
in the self-medication segment at +15.9%(4),
a score made possible by Loceryl® and
Cetaphil®, a range of products used in as-
sociation with derma tology prescribed treat-
ments. As for the aesthetic and corrective
dermatology product portfolio, this once
again provided an impressive platform for
growth. Held back by the economic crisis in
Europe, it is expanding spectacularly in the
New Markets. In order to continue growing,
GALDERMA can rely on a complete spec-
trum of solutions for medical practitioners
in aesthetic and corrective dermatology;
with its hyaluronic acid-based dermal fillers
(Restylane® and Emervel®), a botulinum
toxin type A (Azzalure®), and complemen-
tary products such as Pliaglis® topical an-
aesthetic cream, and the photosensitiser
Metvix® (for non-melanoma skin cancer).
CHINA’S TREMENDOUS POTENTIAL
By 2015, China will be the second-largest pharmaceutical market
in the world. GALDERMA has been operating there for several years,
and 2012 marked the beginning of its expansion in this area,
with the inauguration of a subsidiary to develop its three segments.
Last year, GALDERMA doubled its sales in this market, which is driven
by self-medication and dermal fillers. The laboratory recorded
double-digit growth in all segments. Boosted by very strong internal
demand, growth is particularly robust for medical solutions in
aesthetic and corrective dermatology, thanks to Restylane®’s wide
reputation in this market. Self-medication drug sales are also a
powerful growth reservoir. GALDERMA is counting on its Cetaphil®
range, which is growing rapidly, to help it conquer market share and
then establish the rest of its portfolio.
ZOOM
2. CETAPHIL®
In 2012, the Cetaphil® range and its key
products, Restoraderm® (atopic skin)
and Dermacontrol® (acne), continued
to gain ground in several different
countries.
1. RESTYLANE®
In the aesthetics segment, GALDERMA is focusing on
the development of the Restylane® skinboosters range.
These new products provide deep hydration for
the skin and improve dermal density, thanks to
the micro-injection of stabilised hyaluronic acid.
3. LOCERYL®
Sales of the anti-fungal product
Loceryl® have shown a significant rise
since it became a self-medication
product in pharmacies.
21 3
69